In the ovarian cancer cohort, the median time to response was 1.3 months and median duration of response was 8.0 months. Post the September 4, 2025 data cutoff date, four uPRs were confirmed and one ...

PMV Pharmaceuticals has reported a 43% response rate in a midphase ovarian cancer trial, putting the biotech on a track it believes will lead to a filing for FDA approval in the first quarter of 2027.

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It’s lead product ...

Confirmed responses were observed in patients whose tumors were TP53 Y220C mutated and KRAS wild-type in eight tumor types, including ovarian, lung, breast, endometrial, head and neck, colorectal, ...

PMV Pharma is laying off 30% of its staff as the precision oncology biotech prioritizes pushing its lead solid tumor candidate toward a phase 2 trial in the coming months. The drug, PC14586, became ...

PRINCETON, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic ...

Given this risk, we thought we'd take a look at whether PMV Pharmaceuticals (NASDAQ:PMVP) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual ...